Tag: Cancer Drugs

Many patients who are diagnosed with cancer will require treatment with cancer drugs. Treatment with cancer drugs is usually led by a doctor known as a medical oncologist.

Sanofi Receives Positive CHMP Opinion for Sarclisa® (isatuximab)

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Sarclisa® (isatuximab). The CHMP recommends Sarclisa in combination with pomali...

CytomX and Astellas Announce Collaboration to Develop Therapies for Treatment of Cancer

biotech-lab
CytomX Therapeutics, Inc. and Astellas Pharma Inc. announced they have entered into a strategic collaboration agreement focused on the discovery, research, development and commercialization of novel T...

Global Cancer Generics Market Trend Analysis

Analysis about the trends that are followed by the cancer generics market at the global and regional level as well as the revolutionizing strategies that have been adopted and supported by the governi...

WHO Highlights a Wide Range of Proven Interventions to Prevent New Cancer Cases

The World Health Organization (WHO) spells out the need to step up cancer services in low and middle-income countries. WHO warns that, if current trends continue, the world will see a 60% increase in ...

Japan’s MHLW Approved Foundation Medicine CDx for Roche’s Rozlytrek in Lung Cancer

japan
Chugai Pharmaceutical, a subsidiary of Roche, announced that Japan's Ministry of Health, Labor, and Welfare has granted additional approval of Foundation Medicine's FoundationOne CDx Cancer Genomic Pr...

NICE Rejected Roche’s Tecentriq for Untreated SCLC in Adults

roche
The UK National Institute for Health and Care Excellence (NICE) has issued draft guidance against routine NHS coverage for Roche's Tecentriq (atezolizumab) in combination with carboplatin and etoposid...

Lynparza Approved for gBRCAm Metastatic Pancreatic Adenocarcinoma Treatment

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that Lynparza (olaparib) has been approved in the US for the maintenance treatme...

FDA Recommended KEYTRUDA for Treatment of Certain Patients with NMIBC

fda
Merck, known as MSD outside the United States and Canada, announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) voted 9-4 in favor of recommending...

GSK Announced Full Results from Belantamab Mafodotin DREAMM-2 Study

gsk
GlaxoSmithKline announced full results from the DREAMM-2 study, with data showing that belantamab mafodotin was associated with an overall response rate (ORR) of 31% in patients with relapsed/refracto...

Bristol-Myers Squibb Presented Positive Clinical Results from CC-486 Study

blood
Bristol-Myers Squibb Company announced clinical results from the QUAZAR AML-001 study, evaluating investigational agent CC-486 as maintenance therapy in a broad population of patients with front-line,...

Ardelyx Announced Positive Results from Tenapanor Study

clinical-trials
Ardelyx, Inc., a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, reported positive topline results from ...

Lenvima Accepted by NMPA for Additional Indication of Differentiated Thyroid Cancer

Eisai Co., Ltd. has announced that LENVIMA (generic name: lenvatinib), the orally available kinase inhibitor discovered by Eisai, has been accepted by the National Medical Products Administration of C...

NICE Approved Pfizer’s Ibrance for Treatment of Metastatic Breast Cancer

pfizer
The UK National Institute for Health and Care Excellence (NICE) has approved Pfizer’s Ibrance (palbociclib) for use in combination with fulvestrant for the treatment of women with hormone receptor pos...

Heraeus Expanded HPAPI Production

Company's multimillion euro investment will enable it to meet growing market demands from clients providing cancer treatments. Heraeus Pharmaceutical Ingredients, a business line of Heraeus Precious ...

3P Biopharmaceuticals, In3Bio to Collaborate in Novel Anti-Tumor Treatment Development

3P Biopharmaceuticals, a contract development and manufacturing organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based bi...

Chugai Anticancer Agent/Anti-PD-L1 Launched in UK

Chugai Pharmaceutical Co., Ltd. announced that an anticancer agent/anti-PD-L1 (Programmed Death-Ligand 1) monoclonal antibody Tecentriq Intravenous Infusion 840 mg has been listed on the National Hea...